Real-World Case Studies on Improving Inclusion in Clinical Trials

Diversity in clinical trials is no longer a secondary consideration; it is a regulatory expectation, ethical mandate, and scientific necessity. Underrepresentation of minority and marginalized populations has long plagued clinical research, limiting generalizability and reinforcing health disparities. However, several organizations and research sponsors have made significant strides toward more inclusive trials by deploying innovative strategies and community-focused approaches.

In this article, we explore real-world case studies where trials achieved measurable success in recruiting underrepresented populations. These examples provide a roadmap for sponsors seeking to meet GMP compliance standards while enhancing equitable trial participation.

Case Study 1: Enhancing Black Representation in Oncology Trials (USA)

Challenge: A major oncology sponsor observed disproportionately low enrollment of Black patients in multiple Phase II trials, despite high disease prevalence in African American communities.

Solutions Implemented:

• Partnered with historically Black medical colleges and urban hospitals
• Trained clinical staff in SOP training pharma and cultural sensitivity
• Created patient education materials tailored to Black communities, reviewed by local advocacy groups
• Offered transportation and childcare stipends to reduce participation barriers

Outcome: Black patient enrollment rose from 4% to 16% over 12 months—exceeding FDA expectations and increasing community trust.

Case Study 2: Using Mobile Clinics to Reach Remote Indigenous Populations (Australia)

Challenge: A diabetes study in Australia struggled to enroll Indigenous Australians due to geographic isolation and historical distrust of medical institutions.

Strategies Deployed:

• Deployed mobile research clinics staffed with Indigenous healthcare professionals
• Translated consent materials into native dialects and recorded audio/video versions
• Involved tribal leaders in site selection and recruitment messaging
• Conducted culturally adapted informed consent processes with community oversight

Outcome: Recruitment goals were exceeded by 30%, and participants reported high satisfaction in post-trial surveys. The trial received commendation from the TGA.

Case Study 3: Latino Inclusion through Community Health Promoters (USA)

Context: A cardiovascular study targeting Hispanic/Latino populations faced language and literacy barriers.

Approach:

• Partnered with Latino community clinics and faith-based organizations
• Engaged bilingual promotores (community health workers) to act as liaisons
• Used mobile texting campaigns with culturally relevant messaging
• Adapted recruitment protocols based on Stability studies to ensure consistent outreach timing

Results: Enrollment of Latino participants increased by 45%, and retention rates remained above 85% due to sustained community engagement.

Case Study 4: Virtual Enrollment for LGBTQ+ Participants (Global)

Background: A biotech firm developing a novel HIV prevention drug sought to include LGBTQ+ participants in multiple countries.

Methods:

• Used virtual enrollment platforms for privacy and geographic reach
• Incorporated inclusive intake forms with gender identity and pronoun options
• Partnered with LGBTQ+ advocacy groups for outreach and protocol review
• Used digital ads on LGBTQ+ platforms and geotargeted recruitment

Impact: Trial saw 40% LGBTQ+ enrollment, with particularly high engagement among transgender participants—fostering data quality and stakeholder praise for inclusive practices.

Lessons Learned Across All Case Studies

• Community trust is built through presence, listening, and shared decision-making
• Inclusion strategies must be tailored—not one-size-fits-all
• Trial teams must be diverse and culturally competent
• Language accessibility is crucial, requiring tools validated through process validation
• Metrics and dashboards are needed to track progress in real time

Key Best Practices for Improving Inclusion

1. Early Community Engagement: Involve advocacy groups during protocol design, not just at enrollment
2. Inclusive Eligibility Criteria: Avoid unnecessary exclusions based on comorbidities or age
3. Localized Site Selection: Choose locations accessible to underserved populations
4. Adaptive Communications: Develop multi-channel, language-specific outreach campaigns
5. Data Transparency: Report inclusion metrics to IRBs, sponsors, and the public

Conclusion: Inclusion Requires Intentional Action

Inclusion in clinical trials doesn’t happen by chance—it requires deliberate planning, cultural sensitivity, and stakeholder collaboration. These case studies illustrate that with the right strategies and mindset, sponsors can overcome historical barriers and design studies that reflect the true diversity of the patient populations they aim to serve. Equitable trials lead to better science, improved trust, and greater societal impact.

Understanding the FDA’s Guidance on Diversity in Clinical Research

In recent years, the U.S. Food and Drug Administration (FDA) has taken bold steps to improve diversity in clinical trials. The lack of adequate representation of racial, ethnic, and other demographic groups has long hindered the generalizability and ethical integrity of research. To address this, the FDA released a draft guidance titled “Diversity Plans to Improve Enrollment of Participants from Underrepresented Racial and Ethnic Populations in Clinical Trials” and has introduced mandatory requirements under FDORA Section 3602.

This article provides a comprehensive overview of the FDA’s current expectations for diversity planning and reporting in clinical research, and how sponsors can remain compliant while promoting inclusive and equitable trial practices.

Why Diversity Matters in Clinical Research

Clinical trial participants should reflect the populations most likely to use the treatment. Without adequate representation, sponsors risk:

• Failing to detect differential safety or efficacy responses
• Excluding real-world populations due to restrictive eligibility
• Regulatory scrutiny or delay in approvals
• Lack of trust from historically marginalized communities

According to the USFDA, diverse participation is crucial for robust drug development and ethical standards of research.

Overview of the FDA’s 2022 Draft Guidance

The FDA’s draft guidance encourages sponsors to submit a “Race and Ethnicity Diversity Plan” early in clinical development. This plan should outline:

1. Enrollment Goals: Target numbers for racial and ethnic representation
2. Demographic Justification: Epidemiological data to support enrollment targets
3. Recruitment Strategies: Site selection, community engagement, and inclusive materials
4. Retention Plans: Addressing logistical and cultural barriers to continued participation

This plan aligns with efforts toward greater transparency and accountability across the drug development continuum.

FDORA Section 3602: Mandating Diversity Plans

In December 2022, the Food and Drug Omnibus Reform Act (FDORA) was enacted, legally requiring diversity action plans for all Phase 3 or pivotal studies. Section 3602 stipulates that:

• Sponsors must submit a diversity action plan with demographic targets and strategy
• Any deviation must be justified and may delay FDA review
• Plans are subject to public reporting and inspection

Failure to comply can affect regulatory timelines and reputational standing.

Building a Compliant Diversity Plan

To align with FDA expectations, a strong diversity plan should include:

• Target enrollment proportions based on U.S. Census and disease prevalence data
• Engagement with advocacy and community-based organizations
• Translated and culturally appropriate consent materials
• Geographically diverse site selection
• Internal DEI training for research staff per Pharmaceutical SOP guidelines

Tracking tools should enable real-time oversight of diversity performance across sites.

Best Practices for Achieving Enrollment Goals

Sponsors can enhance success by implementing:

1. Inclusive Protocol Design: Avoid exclusion criteria that disproportionately affect minorities
2. Community Trust Building: Partner with local leaders, churches, and non-profits
3. Bilingual/Bicultural Staff: Improves participant communication and comfort
4. Logistical Support: Transportation, childcare, and flexible visit windows
5. Digital Engagement: Use social media and mobile apps targeted at underrepresented populations

Case Example: Alzheimer’s Trial Meeting FDA Diversity Goals

A global Phase 3 Alzheimer’s trial integrated a Race and Ethnicity Diversity Plan from the start. The sponsor:

• Used epidemiological models to set Hispanic and African American enrollment targets
• Incentivized sites to meet diversity metrics
• Trained staff using SOP validation in pharma protocols for patient engagement
• Held community events in both English and Spanish

Outcome: 24% of participants were from underrepresented racial or ethnic groups, surpassing FDA-recommended benchmarks.

Monitoring and Reporting Metrics

Key metrics that sponsors should monitor include:

• Enrollment by race and ethnicity over time
• Site-level performance on inclusion goals
• Participant dropout stratified by demographic group
• Post-study follow-up rates by subgroup

These metrics can be aligned with ongoing Stability Studies or internal audits for quality assurance.

Preparing for FDA Inspections and Submissions

To avoid inspection findings or review delays:

• Document all diversity-related decisions and justifications
• Maintain complete records of community outreach and engagement activities
• Use standardized formats for reporting diversity data
• Incorporate diversity performance into investigator meetings and site monitoring

Conclusion: A New Era of Inclusive Research

The FDA’s guidance and legal mandates mark a paradigm shift in how clinical research is conducted. Sponsors must now approach diversity with the same rigor as efficacy and safety. By embracing these changes proactively—through strategic planning, community partnerships, and data-driven recruitment—clinical trials can become more inclusive, equitable, and scientifically valid.

How to Strategically Increase Diversity in Clinical Trials

Diversity in clinical trials isn’t just a social imperative—it’s a scientific and regulatory one. Increasing participation among underrepresented groups ensures that research findings are applicable to the populations most affected by disease. Yet, many studies continue to lack adequate representation of racial and ethnic minorities, elderly populations, women, rural communities, and economically disadvantaged patients. Regulatory agencies like the USFDA have issued guidelines emphasizing the need for inclusive enrollment strategies and diversity action plans in trial submissions.

This tutorial explores practical, ethical, and effective strategies to increase diversity and equity in clinical trial participation while maintaining scientific rigor and regulatory compliance.

Why Clinical Trial Diversity Matters

Population heterogeneity impacts disease presentation, drug metabolism, efficacy, and safety profiles. Lack of representation can lead to inaccurate dosing, missed adverse events, and inequitable access to emerging therapies.

• Scientific validity: Diverse data supports subgroup analyses and generalizable results.
• Ethical obligation: All populations deserve a chance to benefit from clinical innovation.
• Regulatory requirement: Agencies like the FDA and EMA require justification for homogeneous study populations.
• Public trust: Transparent, inclusive trials enhance trust among underserved communities.

Common Barriers to Diverse Participation

• Mistrust in healthcare systems due to historical abuses (e.g., Tuskegee study).
• Language barriers and lack of culturally sensitive communication.
• Geographic inaccessibility of research sites, especially in rural and underserved areas.
• Socioeconomic constraints like transportation, childcare, and time off work.
• Strict inclusion/exclusion criteria that unintentionally exclude diverse patients.

Strategies to Increase Trial Diversity

Trial sponsors, CROs, and sites must adopt proactive, multi-faceted approaches. Below are effective strategies for improving diversity:

1. Community Partnerships and Outreach

Build long-term relationships with community organizations, patient advocacy groups, and local clinics.

• Conduct town hall meetings and educational workshops.
• Partner with faith-based organizations, cultural centers, and minority health professionals.
• Engage community health workers as trusted messengers.

2. Inclusive Study Design

During protocol development, ensure that eligibility criteria are not overly restrictive.

• Use real-world data to define relevant inclusion/exclusion factors.
• Include input from diverse advisory boards during protocol review.
• Incorporate remote visits, telehealth, and flexible scheduling to remove logistical barriers.

3. Culturally Competent Materials

Translate trial materials using professional, culturally attuned translators—not just word-for-word translations.

• Adapt materials for readability and relevance to different cultures.
• Provide digital tools with multilingual support and Stability testing protocols that account for local tech conditions.
• Use videos, infographics, and mobile-friendly consent platforms.

4. Site Selection and Expansion

Diversify where trials are conducted.

• Expand to federally qualified health centers (FQHCs), tribal clinics, and community hospitals.
• Train new research-naïve sites in underserved areas using tools like Pharma SOPs and templates.
• Provide infrastructure support to community sites for data entry, EDC use, and patient management.

5. Patient-Centered Recruitment Campaigns

Use digital advertising and social media to reach underrepresented groups.

• Create campaigns tailored to cultural values and linguistic preferences.
• Show diverse imagery and testimonials from past participants.
• Use trusted spokespeople—doctors, clergy, local leaders.

Best Practices in Monitoring and Measuring Diversity

Include measurable goals in trial planning and regularly report on enrollment metrics:

• Track race, ethnicity, gender, age, socioeconomic status, and geography.
• Use dashboards to identify gaps in real-time and course correct.
• Incorporate feedback from diverse patient panels to improve materials and protocols.

Technology platforms should enable analytics that tie engagement efforts directly to recruitment outcomes. This supports adaptive trial management and audit-readiness.

Ethical and Regulatory Considerations

As per EMA and FDA guidance:

• Diversity plans must be submitted for pivotal Phase III trials.
• Data on race and ethnicity must be collected using standardized formats.
• IRBs must review cultural appropriateness of outreach materials.
• Compensation must be equitable and not coercive, especially for low-income populations.

Ensure systems used are validated through equipment qualification and are accessible across digital literacy levels.

Case Study: Improving Black and Latino Representation in a Cardiovascular Trial

A U.S.-based cardiovascular study implemented the following actions:

• Partnered with Black churches and Latino community health centers
• Deployed bilingual eConsent tools
• Provided transportation vouchers and child care stipends
• Trained coordinators in cultural competency

As a result, Black and Latino participation increased by 43% over previous studies in the same indication.

Conclusion: Diversity Is a Strategic Imperative

Improving clinical trial diversity isn’t an optional initiative—it’s essential for credible, equitable, and globally applicable science. By embedding diversity into every phase—from protocol to platform to patient communication—sponsors and researchers can ensure that no population is left behind. Implementing these strategies not only meets regulatory expectations but fosters lasting trust, better science, and broader access to life-saving treatments.